马应龙：子公司获药品注册证书

Core Viewpoint - The company announced that its subsidiary, Jiangxi Mayinglong Meikang Pharmaceutical Co., Ltd., has received the drug registration certificate for Olopatadine Hydrochloride Eye Drops from the National Medical Products Administration, indicating a significant step in expanding its product offerings in the ophthalmic market [1] Group 1 - The approved product, Olopatadine Hydrochloride Eye Drops, is intended for the treatment of allergic conjunctivitis-related eye itching [1]